The market's resilience in the face of such an ugly threat has many market players trying to find ways to reconcile the movement with the news flow.
Refiner has now met or exceeded analysts' EPS estimates for 15 quarters in a row, a very impressive streak given the cyclical nature of the oil industry.
There are multiple reasons why these stocks often decline after their drugs receive the blessing of regulators.
Some of the best opportunities are in lesser-known niche markets such as medical devices and services.
Alexion Pharmaceuticals and Lantheus Holdings are interesting names at current trading levels.
These undervalued names fit well in a diversified portfolio.
Dynavax Technologies and Omeros Corp. have tested shareholders' patience over time and again are at inflection points.
Recent viewership strength will likely support continued premium pricing on NFL programming, while streaming viewership of the 'Big Game' has exploded in recent years.
This trio of reasons plus a chart that remains in a bull channel all point to a stock that should continue to outperform the markets in 2020.
Tesla has the 3 key ingredients that help a loss-making company to succeed: the brute force of the founder, the unbelievable nature of the product and breathtaking execution.